Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2011-05-10
2011-05-10
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093100, C424S093200, C424S093210, C424S093700, C435S069100, C435S320100, C435S325000, C435S455000, C514S04400A
Reexamination Certificate
active
07939063
ABSTRACT:
Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is a secretory cell. The cell is a megakaryotic progenitor cell, or a cell further differentiated therefrom, such as a platelet. The cell is a granulocyte/macrophage progenitor cell or a cell further differentiated therefrom, such as a mast cell or neutrophils. Such host cells containing the molecule or the molecule itself are employed in methods for treating or preventing infection, inflammation or vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage.
REFERENCES:
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 6348185 (2002-02-01), Piwnica-Worms
patent: WO-92/06190 (1992-04-01), None
patent: WO-03/035697 (2003-05-01), None
patent: WO-03/035892 (2003-05-01), None
Anderson, “Human Gene Therapy”, Nature, 392:25-30 (Apr. 30, 1998).
Bdeir et al., “Urokinase mediates fibrinolysis in the pulmonary microvasculature”, Blood, 96(5):1820-1826 (Sep. 1, 2000).
Booth et al., “Plasminogen activator inhibitor (PAI-1) in plasma and platelets”, Brit. J. Haematol. 70:327-333 (Nov. 1988).
Booth et al., “Lysis of platelet-rich thrombi: the role of PAI-1”, Ann. N. Y. Acad. Sci., 667:70-80 (Dec. 1992).
Chaloin et al., “Conformations of primary amphipathic carrier peptides in membrane mimicking environments”, Biochem., 36(37):11179-11187 (Sep. 16, 1997).
Chaloin et al., “Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties”, Biochem. Biophys. Res. Commun., 243(2):601-608 (Feb. 13, 1998).
Couzin et al., “As Gelsinger Case Ends, Gene Therapy Suffers Another Blow”, Science, 307:1028 (Feb. 18, 2005).
Declerck et al., “Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay”, Blood, 71:220-225 (Jan. 1998).
Fay et al., “Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms”, Blood, 83:351-356 (Jan. 15, 1994).
Fay et al., “Vitronectin inhibits the thrombotic response to arterial injury in mice”, Blood, 93(6):1825-1830 (Mar. 15, 1999).
Futaki et al., “Structural variety of membrane permeable peptides”, Curr. Protein Pept. Sci., 4(2):87-96 (Apr. 2003).
Futaki, “Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms”, Int. J. Pharm., 245(1-2):1-7 (Oct. 1, 2002).
Goncalves, “A Concise Peer Into the Background, Initial Thoughts, and Practices of Human Gene Therapy”, Bioessays, 27(5):506-517 (2005).
Hayward et al, “Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules”, Blood, 89:1243-1253 (Feb. 15, 1997).
Hayward et al., “Fibrinogen degradation products in patients with the Quebec platelet disorder”, Brit. J. Haematol., 97:497-503 (May 1997).
Hayward et al., “An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect”, Blood, 87(12):4967-4978 (Jun. 15, 1996).
Holt et al., “Secretion of plasminogen by washed human platelets”, Abstracts Circulation, 62(3):342, No. 1321 (Oct. 1980).
Holt et al., “Biochemistry of alpha granule proteins”, Sem. Hematol., 22:151-163 (Apr. 1985).
Jiang et al., “Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes”, Blood, 87:2775-2781 (Apr. 1, 1996).
Juengst, “What's Next for Human Gene Therapy”, BMJ, 326:1410-1411 (Jun. 28, 2003).
Kahr et al., “Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator”, Blood, 98:257-265 (Jul. 15, 2001).
Kruithof et al., “Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation”, Blood, 70:1645-1653 (Nov. 1987).
Kufrin et al., “Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets”, Blood, 102(3):926-933 (Aug. 1, 2003).
Lenich et al., “Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator”, Blood, 90:3579-3586 (Nov. 1, 1997).
Morris et al., “A peptide carrier for the delivery of biologically active proteins into mammalian cells”, Nat. Biotechnol., 19(12):1173-1176 (Dec. 2001).
Ravid et al., “Targeted Expression of a Conditional Oncogene in Hematopoietic Cells of Transfenic Mice”, J. Cell Biol. 123(6 Pt 1):1545-1553 (Dec. 1993).
Ravid et al., “Selective Targeting of Gene Products with the Megakaryocyte Platelet Factor 4 Promoteter”, Proc. Natl. Acad Sci USA, 88(4):1521-1525 (Feb. 1991).
Rosenberg et al., “Gene Therapist, Heal Thyself”, Science, 287:1751 (Mar. 10, 2000).
Taylor et al., “Delivery of bioactive, gel-isolated proteins into live cells”, Electrophoresis, 24(9):1331-1337 (May 2003).
Touchette et al., “Gene Therapy: Not Ready for Prime Time”, Nature Med., 2(1):7-8 (Jan. 1996).
Vives et al., “TAT peptide internalization: seeking the mechanism of entry”, Curr. Protein Pept. Sci., 4(2):125-132 (Apr. 2003).
Cines Douglas B.
Poncz Mortimer
Howson & Howson LLP
Kaushal Sumesh
The Children's Hospital of Philadelphia
The Trustees of the University of Pennsylvania
LandOfFree
Delivery vehicle for recombinant proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery vehicle for recombinant proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery vehicle for recombinant proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650225